Bivalirudin
Angiomax — the workhorse direct thrombin inhibitor for percutaneous coronary intervention. FDA-approved December 2000 (The Medicines Company, now Sandoz); the first synthetic peptide DTI to achieve broad PCI adoption. REPLACE-2, ACUITY, and HORIZONS-AMI trials established the anticoagulant profile; subsequent MATRIX trial outcomes shifted practice in some populations back toward heparin.
A synthetic bivalent direct thrombin inhibitor rationally designed from structural studies of hirudin. The 20-residue peptide combines a hirudin-derived C-terminal dodecapeptide (that binds thrombin's anion-binding exosite 1, the fibrinogen-binding site) with an N-terminal D-Phe-Pro-Arg-Pro tetrapeptide (that binds thrombin's catalytic site), connected by a tetraglycine spacer. Unlike hirudin, bivalirudin binding to thrombin is transient because thrombin itself slowly cleaves the Arg3-Pro4 bond, releasing the N-terminal tetrapeptide and restoring thrombin catalytic activity — this gives the drug a predictable ~25-minute plasma half-life and reduces bleeding risk relative to irreversible DTIs. FDA-approved December 15, 2000 as Angiomax® by The Medicines Company (later acquired by Novartis in 2020; now Sandoz under the 2023 Novartis Sandoz spin-off) for use with aspirin in patients undergoing percutaneous coronary intervention. Label expanded 2005 (REPLACE-2) for broader PCI use and for patients with heparin-induced thrombocytopenia (ATBAT). Subsequently 2015 MATRIX and other trials triggered practice-pattern shifts in which bivalirudin's advantage over heparin narrowed; it remains a mainstay in HIT and in bleeding-risk PCI populations.
Mechanism of action
Bivalent direct thrombin inhibitor. The C-terminal hirudin-derived dodecapeptide (residues 9–20) occupies thrombin's exosite 1 (fibrinogen-binding site), preventing substrate recognition. The N-terminal D-Phe-Pro-Arg-Pro tetrapeptide (residues 1–4) occupies thrombin's active site, blocking catalytic activity. The tetraglycine linker allows both ends to engage simultaneously, producing high-affinity bivalent binding. Crucially, the Arg3-Pro4 peptide bond is slowly hydrolyzed by bound thrombin itself — a "self-destructing" inhibitor — which releases the N-terminal tetrapeptide and restores catalytic activity at a kinetically predictable rate. This self-limiting mechanism gives bivalirudin a much more predictable pharmacokinetic profile than irreversible DTIs and contributes to its lower bleeding risk. Bivalirudin inhibits both free and clot-bound thrombin (unlike heparin, which only inhibits free thrombin via antithrombin). No dependence on antithrombin; no risk of heparin-induced thrombocytopenia.
Primary uses
- Anticoagulation during percutaneous coronary intervention (FDA-approved)
- PCI in patients with heparin-induced thrombocytopenia (FDA-approved)
- PCI in patients at high risk of bleeding (common off-label / guideline-supported indication)
Typical dosing
Dose reduction required in severe renal impairment (CrCl <30 mL/min: infusion reduced to 1 mg/kg/h). Hemodialyzable — can be removed if excessive anticoagulation. Monitoring by activated clotting time (ACT) optional during PCI.
Regulatory status
FDA-approved December 15, 2000 (Angiomax®, The Medicines Company, NDA 20873) as an anticoagulant for patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, in conjunction with aspirin. Label expanded 2005 for use with or without GP IIb/IIIa inhibition in PCI (post-REPLACE-2). Further label expansion for heparin-induced thrombocytopenia (HIT) with or without thrombosis undergoing PCI (post-ATBAT). The Medicines Company was acquired by Novartis in 2020; Angiomax is now part of Sandoz (Novartis generics spin-off, 2023). Multiple generic bivalirudin products available since patent expiration.
References
- [fda-pi] Angiomax® (bivalirudin) for Injection Prescribing Information. The Medicines Company / Sandoz. Initial US approval December 15, 2000 (NDA 20873).
- [clinical-trial] Lincoff AM, Bittl JA, Harrington RA, et al. "Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention (REPLACE-2)." JAMA, 2003;289(7):853-863.
- [clinical-trial] Stone GW, Witzenbichler B, Guagliumi G, et al. "Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)." N Engl J Med, 2008;358(21):2218-2230.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.